secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001437749-23-031669
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica amends ReMEDy2 stroke trial protocol; cash $56.2M with runway to 2026
-------------------------------------------------------------------------------

- FDA 30-day review of protocol amendments passed without comment; changes focus on moderate anterior circulation strokes (NIHSS 5-15).
- Initial US clinical site activations expected in Nov-Dec 2023; full enrollment for interim analysis targeted by 2024.
- Cash and investments $56.2M as of Sep 30, 2023, up from $33.5M at Dec 31, 2022; cash runway into 2026.
- Q3 2023 R&D expenses $3.3M (vs $1.6M Q3 2022); G&A $1.9M (vs $1.5M); net cash used in operations $14.9M for nine months (vs $8.7M prior).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/0001437749-23-031669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923031669/dmtp20231112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer